{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:35:23Z","timestamp":1781138123138,"version":"3.54.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2006,7,26]],"date-time":"2006-07-26T00:00:00Z","timestamp":1153872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1038\/sj.npp.1301146","type":"journal-article","created":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T15:38:41Z","timestamp":1154446721000},"page":"2537-2551","source":"Crossref","is-referenced-by-count":82,"title":["Relative Abuse Liability of GHB in Humans: A Comparison of Psychomotor, Subjective, and Cognitive Effects of Supratherapeutic Doses of Triazolam, Pentobarbital, and GHB"],"prefix":"10.1038","volume":"31","author":[{"given":"Lawrence P","family":"Carter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam Z","family":"Mintzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland R","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,7,26]]},"reference":[{"key":"BF1301146_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/oxfordjournals.alcalc.a008160","volume":"31","author":"G Addolorato","year":"1996","unstructured":"Addolorato G, Castelli E, Stefanini GF, Casella G, Caputo F, Marsigli L et al (1996). An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. GHB Study Group. Alcohol Alcohol 31: 341\u2013345.","journal-title":"Alcohol Alcohol"},{"key":"BF1301146_CR2","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1081\/JA-200066866","volume":"40","author":"SP Barrett","year":"2005","unstructured":"Barrett SP, Gross SR, Garand I, Pihl RO (2005). Patterns of simultaneous polysubstance use in Canadian rave attendees. Subst Use Misuse 40: 1525\u20131537.","journal-title":"Subst Use Misuse"},{"key":"BF1301146_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/BF02806009","volume":"127","author":"PM Beardsley","year":"1996","unstructured":"Beardsley PM, Balster RL, Harris LS (1996). Evaluation of the discriminative stimulus and reinforcing effects of gammahydroxybutyrate (GHB). Psychopharmacology 127: 315\u2013322.","journal-title":"Psychopharmacology"},{"key":"BF1301146_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0741-8329(99)00085-3","volume":"20","author":"F Begh\u00e8","year":"2000","unstructured":"Begh\u00e8 F, Carpanini MT (2000). Safey and tolerability of gamma-hydroxybutyrc acid in the treatment of alcohol-dependent patients. Alcohol 20: 223\u2013225.","journal-title":"Alcohol"},{"key":"BF1301146_CR5","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1111\/j.1360-0443.2003.00554.x","volume":"98","author":"MA Bellis","year":"2003","unstructured":"Bellis MA, Hughes K, Bennett A, Thomson R (2003). The role of an international nightlife resort in the proliferation of recreational drugs. Addiction 98: 1713\u20131721.","journal-title":"Addiction"},{"key":"BF1301146_CR6","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/0024-3205(82)90624-5","volume":"30","author":"J Benavides","year":"1982","unstructured":"Benavides J, Rumigny JF, Bourguignon JJ, Cash C, Wermuth CG, Mandel P et al (1982). High affinity binding sites for gamma-hydroxybutyric acid in rat brain. Life Sci 30: 953\u2013961.","journal-title":"Life Sci"},{"key":"BF1301146_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/0091270003262795","volume":"44","author":"LA Borgen","year":"2004","unstructured":"Borgen LA, Okerholm RA, Lai A, Scharf MB (2004). The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients. J Clin Pharmacol 44: 253\u2013257.","journal-title":"J Clin Pharmacol"},{"key":"BF1301146_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0379-0738(03)00044-6","volume":"133","author":"IJ Bosman","year":"2003","unstructured":"Bosman IJ, Lusthof KJ (2003). Forensic cases involving the use of GHB in The Netherlands. Forensic Sci Int 133: 17\u201321.","journal-title":"Forensic Sci Int"},{"key":"BF1301146_CR9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.5694\/j.1326-5377.2004.tb06295.x","volume":"181","author":"DG Caldicott","year":"2004","unstructured":"Caldicott DG, Chow FY, Burns BJ, Felgate PD, Byard RW (2004). Fatalities associated with the use of gamma-hydroxybutyrate and its analogues in Australasia. Med J Aust 181: 310\u2013313.","journal-title":"Med J Aust"},{"key":"BF1301146_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0014-2999(95)00493-5","volume":"285","author":"G Colombo","year":"1995","unstructured":"Colombo G, Agabio R, Balaklievskaia N, Diaz G, Lobina C, Reali R et al (1995). Oral self-administration of gamma-hydroxybutyric acid in the rat. Eur J Pharmacol 285: 103\u2013107.","journal-title":"Eur J Pharmacol"},{"key":"BF1301146_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0031-9384(98)00033-X","volume":"64","author":"G Colombo","year":"1998","unstructured":"Colombo G, Agabio R, Diaz G, Fa M, Lobina C, Reali R et al (1998). Gamma-hydroxybutyric acid intake in ethanol-preferring sP and nonpreferring sNP rats. Physiol Behav 64: 197\u2013202.","journal-title":"Physiol Behav"},{"key":"BF1301146_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/jat\/28.6.481","volume":"28","author":"FJ Couper","year":"2004","unstructured":"Couper FJ, Thatcher JE, Logan BK (2004). Suspected GHB overdoses in the emergency department. J Anal Toxicol 28: 481\u2013484.","journal-title":"J Anal Toxicol"},{"key":"BF1301146_CR13","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1081\/JA-200066777","volume":"40","author":"L Degenhardt","year":"2005","unstructured":"Degenhardt L, Copeland J, Dillon P (2005). Recent trends in the use of \u2018club drugs\u2019: an Australian review. Subst Use Misuse 40: 1241\u20131256.","journal-title":"Subst Use Misuse"},{"key":"BF1301146_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0376-8716(02)00017-0","volume":"67","author":"L Degenhardt","year":"2002","unstructured":"Degenhardt L, Darke S, Dillon P (2002). GHB use among Australians: characteristics, use patterns and associated harm. Drug Alcohol Depend 67: 89\u201394.","journal-title":"Drug Alcohol Depend"},{"key":"BF1301146_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1046\/j.1360-0443.2003.00265.x","volume":"98","author":"L Degenhardt","year":"2003","unstructured":"Degenhardt L, Darke S, Dillon P (2003). The prevalence and correlates of gamma-hydroxybutyrate (GHB) overdose among Australian users. Addiction 98: 199\u2013204.","journal-title":"Addiction"},{"key":"BF1301146_CR16","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1097\/00001756-200107200-00039","volume":"12","author":"L Fattore","year":"2001","unstructured":"Fattore L, Cossu G, Martellotta C, Deiana S, Fratta W (2001). Baclofen antagonises intravenous self-administration of \u03b3-hydroxybutyric acid in mice. Neuroreport 12: 2243\u20132246.","journal-title":"Neuroreport"},{"key":"BF1301146_CR17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s002280050560","volume":"54","author":"SD Ferrara","year":"1999","unstructured":"Ferrara SD, Giorgetti R, Zancaner S, Orlando R, Tagliabracci A, Cavarzeran F et al (1999). Effects of single dose gamma-hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy volunteers. Eur J Clin Pharmacol 54: 821\u2013827.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF1301146_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0740-5472(02)00267-2","volume":"23","author":"TE Freese","year":"2002","unstructured":"Freese TE, Miotto K, Reback CJ (2002). The effects and consequences of selected club drugs. J Subst Abuse Treat 23: 151\u2013156.","journal-title":"J Subst Abuse Treat"},{"key":"BF1301146_CR19","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1592\/phco.23.10.1205.32756","volume":"23","author":"DE Fuller","year":"2003","unstructured":"Fuller DE, Hornfeldt CS (2003). From club drug to orphan drug: sodium oxybate (Xyrem) for the treatment of cataplexy. Pharmacotherapy 23: 1205\u20131209.","journal-title":"Pharmacotherapy"},{"key":"BF1301146_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1360-0443.1997.tb03640.x","volume":"92","author":"GP Galloway","year":"1997","unstructured":"Galloway GP, Frederick SL, Staggers FE, Gonzales M, Stalcup SA, Smith DE (1997). Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 92: 89\u201396.","journal-title":"Addiction"},{"key":"BF1301146_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/0269881105049041","volume":"19","author":"A Gonzalez","year":"2005","unstructured":"Gonzalez A, Nutt DJ (2005). Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol 19: 195\u2013204.","journal-title":"J Psychopharmacol"},{"key":"BF1301146_CR22","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/S0376-8716(03)00098-X","volume":"70","author":"RR Griffiths","year":"2003","unstructured":"Griffiths RR, Bigelow GE, Ator NA (2003). Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend 70: S41\u2013S54.","journal-title":"Drug Alcohol Depend"},{"key":"BF1301146_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/archpsyc.1983.01790070055007","volume":"40","author":"RR Griffiths","year":"1983","unstructured":"Griffiths RR, Bigelow GE, Liebson I (1983). Differential effects of diazepam and pentobarbital on mood and behavior. Arch Gen Psychiatry 40: 865\u2013873.","journal-title":"Arch Gen Psychiatry"},{"key":"BF1301146_CR24","first-page":"649","volume":"215","author":"RR Griffiths","year":"1980","unstructured":"Griffiths RR, Bigelow GE, Liebson I, Kaliszak JE (1980). Drug preference in humans: double-blind choice comparison of pentobarbital, diazepam and placebo. J Pharmacol Exp Ther 215: 649\u2013661.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1301146_CR25","first-page":"31","volume":"9","author":"RR Griffiths","year":"2005","unstructured":"Griffiths RR, Johnson MW (2005). Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 9: 31\u201341.","journal-title":"J Clin Psychiatry"},{"key":"BF1301146_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0149-7634(85)90039-9","volume":"9","author":"RR Griffiths","year":"1985","unstructured":"Griffiths RR, Lamb RJ, Ator NA, Roache JD, Brady JV (1985). Relative abuse liability of triazolam: experimental assessment in animals and humans. Neurosci Biobehav Rev 9: 133\u2013151.","journal-title":"Neurosci Biobehav Rev"},{"key":"BF1301146_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF00432169","volume":"75","author":"RR Griffiths","year":"1981","unstructured":"Griffiths RR, Lukas SE, Bradford LD, Brady JV, Snell JD (1981). Self-injection of barbiturates and benzodiazepines in baboons. Psychopharmacology 75: 101\u2013109.","journal-title":"Psychopharmacology"},{"key":"BF1301146_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00008877-199302000-00001","volume":"4","author":"RR Griffiths","year":"1993","unstructured":"Griffiths RR, Troisi JR, Silverman K, Mumford GK (1993). Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav Pharmacol 4: 3\u201313.","journal-title":"Behav Pharmacol"},{"key":"BF1301146_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/bja\/43.2.113","volume":"43","author":"IG Grove-White","year":"1971","unstructured":"Grove-White IG, Kelman GR (1971). Effect of methohexitone, diazepam and sodium 4-hydroxybutyrate on short-term memory. Br J Anaesth 43: 113\u2013116.","journal-title":"Br J Anaesth"},{"key":"BF1301146_CR30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1749-6632.2002.tb04186.x","volume":"965","author":"Y Itzhak","year":"2002","unstructured":"Itzhak Y, Ali SF (2002). Repeated administration of gamma-hydroxybutyric acid (GHB) to mice: assessment of the sedative and rewarding effects of GHB. Ann NY Acad Sci 965: 451\u2013460.","journal-title":"Ann NY Acad Sci"},{"key":"BF1301146_CR31","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/jat\/29.6.582","volume":"29","author":"P Kintz","year":"2005","unstructured":"Kintz P, Villain M, P\u00e9lissier A, Cirimele V, Leonetti G (2005). Unusually high concentrations in a fatal GHB case. J Anal Toxicol 29: 582\u2013585.","journal-title":"J Anal Toxicol"},{"key":"BF1301146_CR32","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.drugalcdep.2005.07.010","volume":"81","author":"ME Liechti","year":"2006","unstructured":"Liechti ME, Kunz I, Greminger P, Speich R, Kupferschmidt H (2006). Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. Drug Alcohol Depend 81: 323\u2013326.","journal-title":"Drug Alcohol Depend"},{"key":"BF1301146_CR33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0301-0082(96)00064-0","volume":"51","author":"M Maitre","year":"1997","unstructured":"Maitre M (1997). The \u00e3-hydroxybutyrate signaling system in brain: organization and functional implications. Prog Neurobiol 51: 337\u2013361.","journal-title":"Prog Neurobiol"},{"key":"BF1301146_CR34","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0924-977X(97)00087-4","volume":"8","author":"MC Martellotta","year":"1998","unstructured":"Martellotta MC, Cossu G, Fattore L, Gessa GL, Fratta W (1998). Intravenous self-administration of gamma-hydroxybutyric acid in drug-na\u00efve mice. Eur Neuropsychopharmacology 8: 293\u2013296.","journal-title":"Eur Neuropsychopharmacology"},{"key":"BF1301146_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s002130050312","volume":"132","author":"MC Martellotta","year":"1997","unstructured":"Martellotta MC, Fattore L, Cossu G, Fratta W (1997). Rewarding properties of gamma-hydroxybutyric acid: an evaluation through place preference paradigm. Psychopharmacology 132: 1\u20135.","journal-title":"Psychopharmacology"},{"key":"BF1301146_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0014-2999(96)00916-8","volume":"321","author":"P Mathivet","year":"1997","unstructured":"Mathivet P, Bernasconi R, De Barry J, Marescaux C, Bittiger H (1997). Binding characteristics of \u03b3-hydroxybutyric acid as a weak but selective GABAB receptor agonist. Eur J Pharmacol 321: 67\u201375.","journal-title":"Eur J Pharmacol"},{"key":"BF1301146_CR37","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3758\/BF03203313","volume":"14","author":"D McLeod","year":"1982","unstructured":"McLeod D, Griffiths RR, Bigelow GE, Yingling J (1982). An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instrum 14: 463\u2013466.","journal-title":"Behav Res Methods Instrum"},{"key":"BF1301146_CR38","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/0013-4694(66)90107-6","volume":"20","author":"DR Metcalf","year":"1966","unstructured":"Metcalf DR, Emde RN, Stripe JT (1966). An EEG-behavioral study of sodium hydroxybutyrate in humans. Electroenceph Clin Neurophysiol 20: 506\u2013512.","journal-title":"Electroenceph Clin Neurophysiol"},{"key":"BF1301146_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0376-8716(98)00110-0","volume":"53","author":"MZ Mintzer","year":"1998","unstructured":"Mintzer MZ, Griffiths RR (1998). Flunitrazepam and triazolam: a comparison of behavioral effects and abuse liability. Drug Alcohol Depend 53: 49\u201366.","journal-title":"Drug Alcohol Depend"},{"key":"BF1301146_CR40","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/01.fbp.0000172736.11994.3c","volume":"16","author":"MZ Mintzer","year":"2005","unstructured":"Mintzer MZ, Griffiths RR (2005). An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers. Behav Pharmacol 16: 579\u2013584.","journal-title":"Behav Pharmacol"},{"key":"BF1301146_CR41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1037\/1064-1297.5.3.203","volume":"5","author":"MZ Mintzer","year":"1997","unstructured":"Mintzer MZ, Guarino J, Kirk T, Roache JD, Griffiths RR (1997). Ethanol and pentobarbital: comparison of behavioral and subjective effects in sedative drug abusers. Exp Clin Psychopharmacol 5: 203\u2013215.","journal-title":"Exp Clin Psychopharmacol"},{"key":"BF1301146_CR42","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/105504901750532111","volume":"10","author":"K Miotto","year":"2001","unstructured":"Miotto K, Darakjian J, Basch J, Murray S, Zogg J, Rawson R (2001). Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 10: 232\u2013241.","journal-title":"Am J Addict"},{"key":"BF1301146_CR43","first-page":"570","volume":"272","author":"GK Mumford","year":"1995","unstructured":"Mumford GK, Rush CR, Griffiths RR (1995). Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. J Pharmacol Exp Ther 272: 570\u2013580.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1301146_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0376-8716(00)00191-5","volume":"63","author":"KL Nicholson","year":"2001","unstructured":"Nicholson KL, Balster RL (2001). GHB: a new and novel drug of abuse. Drug Alcohol Depend 63: 1\u201322.","journal-title":"Drug Alcohol Depend"},{"key":"BF1301146_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/alcalc\/34.1.15","volume":"34","author":"F Poldrugo","year":"1999","unstructured":"Poldrugo F, Addolorato G (1999). The role of \u03b3-hydroxybutyric acid in the treatment of alcoholism: from animal to clinical studies. Alcohol Alcohol 34: 15\u201324.","journal-title":"Alcohol Alcohol"},{"key":"BF1301146_CR46","first-page":"120","volume":"234","author":"JD Roache","year":"1985","unstructured":"Roache JD, Griffiths RR (1985). Comparison of triazolam and pentobarbital: performance impairment, subjective effects and abuse liability. J Pharmacol Exp Ther 234: 120\u2013133.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1301146_CR47","first-page":"978","volume":"243","author":"JD Roache","year":"1987","unstructured":"Roache JD, Griffiths RR (1987). Lorazepam and meprobamate dose effects in humans: behavioral effects and abuse liability. J Pharmacol Exp Ther 243: 978\u2013988.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1301146_CR48","first-page":"25","volume":"11","author":"F Romanelli","year":"2003","unstructured":"Romanelli F, Smith KM, Pomeroy C (2003). Use of club drugs by HIV-seropositive and HIV-seronegative gay and bisexual men. Top HIV Med 11: 25\u201332.","journal-title":"Top HIV Med"},{"key":"BF1301146_CR49","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0740-5472(96)00157-2","volume":"14","author":"MI Rosen","year":"1997","unstructured":"Rosen MI, Pearsall HR, Woods SW, Kosten TR (1997). Effects of gamma-hydroxybutyric acid (GHB) in opioid-dependent patients. J Subst Abuse Treat 14: 149\u2013154.","journal-title":"J Subst Abuse Treat"},{"key":"BF1301146_CR50","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s002130051030","volume":"145","author":"CR Rush","year":"1999","unstructured":"Rush CR, Frey JM, Griffiths RR (1999). Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology 145: 39\u201351.","journal-title":"Psychopharmacology"},{"key":"BF1301146_CR51","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/00007611-200093060-00002","volume":"93","author":"RH Schwartz","year":"2000","unstructured":"Schwartz RH, Milteer R, LeBeau MA (2000). Drug facilitated sexual assault (\u2018date rape\u2019). South Med J 93: 558\u2013561.","journal-title":"South Med J"},{"key":"BF1301146_CR52","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1037\/0096-3445.117.1.34","volume":"117","author":"JG Snodgrass","year":"1988","unstructured":"Snodgrass JG, Corwin J (1988). Pragmatics of measuring recognition memory: applications to dementia and amnesia. J Exp Psychcol Gen 117: 34\u201350.","journal-title":"J Exp Psychcol Gen"},{"key":"BF1301146_CR53","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1136\/emj.2002.002402","volume":"21","author":"M Varela","year":"2004","unstructured":"Varela M, Nogue S, Oros M, Miro O (2004). Gamma hydroxybutyrate use for sexual assault. Emerg Med J 21: 255\u2013256.","journal-title":"Emerg Med J"},{"key":"BF1301146_CR54","doi-asserted-by":"publisher","DOI":"10.1037\/11167-000","volume-title":"The Measurement and Appraisal of Adult Intelligence","author":"D Wechsler","year":"1958","unstructured":"Wechsler D (1958). The Measurement and Appraisal of Adult Intelligence. Williams & Wilkins: Baltimore, MD."},{"key":"BF1301146_CR55","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0376-8716(98)00153-7","volume":"54","author":"WL Woolverton","year":"1999","unstructured":"Woolverton WL, Rowlett JK, Winger G, Woods JH, Gerak LR, France CP (1999). Evaluation of the reinforcing and discriminative stimulus effects of \u03b3-hydroxybutyrate in rhesus monkeys. Drug Alcohol Depend 54: 137\u2013143.","journal-title":"Drug Alcohol Depend"},{"key":"BF1301146_CR56","first-page":"269","volume":"23","author":"LA Zawertailo","year":"2003","unstructured":"Zawertailo LA, Busto UE, Kaplan HL, Greenblatt DJ, Sellers EM (2003). Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. J Clin Psychopharmacol 23: 269\u2013280.","journal-title":"J Clin Psychopharmacol"},{"key":"BF1301146_CR57","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1056\/NEJM200101113440202","volume":"344","author":"DL Zvosec","year":"2001","unstructured":"Zvosec DL, Smith SW, McCutcheon JR, Spillane J, Hall BJ, Peacock EA (2001). Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 344: 87\u201394.","journal-title":"N Engl J Med"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/1301146.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1301146","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1301146.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T06:51:58Z","timestamp":1684219918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1301146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,26]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["BF1301146"],"URL":"https:\/\/doi.org\/10.1038\/sj.npp.1301146","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,26]]}}}